There are several therapeutic options for the treatment of benign prostatic hyperplasia: pharmacological treatment, aimed at improving quality of life by alleviating dysuric symptoms; watchful waiting for patients at low risk of disease progression; and surgical treatment, usually transurethral prostatectomy (TURP).
The choice of each treatment option requires a risk-benefit assessment, and this assessment is often entrusted to the physician, who must determine whether there are indications for surgery.
The “Hospitalization for Transurethral Prostatectomy for Benign Prostatic Hyperplasia” indicator measures the variability of hospitalization rates between geographic areas and identifies potential over- or under-use of the surgical technique, since it is unlikely that the indications for TURP will vary systematically between the areas considered.
Your doctor will address your concerns and guide you in making an informed decision about the treatment path to follow.Contact him to get all the information you need for your health needs.
Indicators 
